Tag Archives: C Diff Foundation Volunteer Patient Advocate Program

November IS C.diff. (Clostridium difficile, C.difficile) Infection Awareness Month – Changing Lives – Saving Lives – Making a Difference With You

YOU CAN make a difference!

How?

Let us show you the ways……

It is as simple as sharing a graphic provided below or by sharing the website which is complete with C.diff. Infection key points on  Prevention, Treatments available, Clinical Trials in progress, Environmental Safety, Infection Prevention, Support, Healthcare Provider updates, Patient and Family resources and much more.

www.cdifffoundation.org

The valuable information located on the website can answer questions that develop during a C.difficile infection.  The website also provides important contact information with  listings of free patient/family programs.

It is empowering to share the information through the printed literature available.  The information will be mailed  to a physical address (not e-mailed) and can be shared with friends, family, health care professionals, and within your community.

Having a conversation —- sharing your story, accompanied with the facts found on the website explaining C.diff. prevention, treatments available, clinical trials, environmental safety, and support worldwide, is both appreciated and powerful.

To receive complimentary brochures, magnets and additional information – please complete the form below:

You are invited to join us in advocating for Cdiff Awareness during the month of November and every month after that because educating and advocating  for C.diff. prevention, treatments available, clinical trials, environmental safety, and support is important every day of the year.

Become a Volunteer Patient Advocate today

Thank you for considering taking steps forward and walking with us to witness a global change and decrease in newly diagnosed Clostridium difficile infections worldwide.

With our sincere gratitude

The Committee Chairs, Patient Advocates, and Members of the C Diff Foundation Worldwide

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Please Note:  ALL personal information submitted will never be shared or sold by the C Diff Foundation.  Name, Address, e-mail address will be utilized for the purpose set forth in this message.
  • Thank you .

 

C Diff Foundation Members Volunteer Over 20k Hours Of Service To Raise Awareness and Educate Worldwide

The C Diff Foundation celebrated ‘National Volunteer Week,’  April 23 – 29 to recognize more than 150 volunteer members around the globe ~ dedicated in raising awareness of C.diff. infection prevention, treatments, environmental safety and support with the C Diff Foundation

 

 

 

and have collectively donated more than 20,000 hours of volunteer service to the Foundation over the past nine months.

Thank you!

We are truly grateful!

Highlights Of the Latest Advances In the Battle Against the Deadly Pathogen – Dale Gerding, MD

TO READ THIS ARTICLE IN ITS ENTIRETY AS PUBLISHED IN THE MD MAGAZINE — PLEASE CLICK ON THE FOLLOWING LINK TO BE REDIRECTED:

 

http://www.mdmag.com/medical-news/c-diff-foundation-highlights-latest-advances-in-the-battle-against-the-deadly-pathogen

In September, researchers, health care workers, and industry and patient advocates convened for the 4th Annual International Raising C. diff Awareness Conference and Health Expo in Atlanta.

Clifford McDonald, MD, Associate Director for Science in the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC), chaired the conference. In his role at the CDC, McDonald’s at the forefront of efforts to prevent and treat the infection – one the CDC has declared among the most urgent drug-resistant threats that we currently face.

“It’s my firm belief that we are on the threshold of a new era in better diagnosis, treatment, and prevention approaches. At the CDC, we deal with statistics, but there are faces behind those numbers. At the heart of every infection is a patient who deserves our competence, our empathy, and our passion,” said McDonald.

One of those faces, Roy Poole, is a volunteer patient advocate for the  C Diff Foundation. After retiring from a career in the Air Force, Poole led a healthy, active lifestyle as an avid outdoors-man in Colorado before antibiotics prescribed for a routine dental procedure set the stage for CDI. In the medical community, his symptoms were met with disbelief and inappropriate treatment.

“Three weeks after leaving the hospital, I walked into my (previous) primary care physician, and asked for an order to have a stool sample taken to determine if Toxins A or B were present. His response was, ‘Are you still having problems with that?’ Clearly, there is a need for more education about C. diff among physicians,” said Poole.

CDI is a formidable opponent. However, with the newly focused attention on discovering ways to disable the bacteria and cohesive public health approaches aimed at prevention, presenters from government, academia and industry offered five key reasons we can win the battle against C. diff:

Antibiotic stewardship efforts are gaining a foothold.
Statistics present a chilling picture: 453,000 new cases and an estimated 30,000 deaths each year. It’s likely that those numbers grossly underestimate the true impact of CDI, since it’s what we know from death certificate reporting.

However, we are seeing that rates may have peaked after a long plateau. Mark Wilcox, MD, Head of Microbiology at Leeds Teaching Hospital, Professor of Medical Microbiology at University of Leeds, and the lead on Clostridium difficile for Public Health England in the United Kingdom, has demonstrated a 70% reduction in cases in England in just 7 years. This was after a concerted effort that Wilcox spearheaded surrounding antibiotic stewardship, specifically addressing a reduction in unnecessary prescribing of fluoroquinolones and cephalosporin antibiotics.

Commonly prescribed antibiotics disrupt the protective microbiota (the normal bacteria of the gut) and leave it vulnerable for C. diff colonization. “There was a concerted effort that went beyond lip service and truly embraced the principles of improved surveillance, more accurate diagnostics, enhanced infection prevention measures to use antibiotics more wisely and to limit transmission and careful treatment,” said Wilcox.

High rates of CDI are always associated with the use of certain antibiotics: clindamycin, cephalosporin, and fluoroquinolones. Research has shown that lower respiratory tract infections and urinary tract infections account for more than 50% of all in-patient antibiotics use. But are these really necessary?

“We know that antibiotics are overused and misused across every healthcare setting. At least 30% of antibiotic prescriptions are unnecessary – and this equates to 47 million unnecessary antibiotic prescriptions per year written in doctors’ offices, hospital outpatient departments, and emergency departments. We have a lot of work to do, and CDC is actively working to reduce unnecessary antibiotic use,” said Arjun Srinivasan, MD at the CDC. “Stopping unnecessary antibiotics is the single most effective thing we can do to curb C. diff infections in the United States. This is something that we can do today.”

Srinivasan acknowledged that telling patients that they can’t have a prescription for an antibiotic might result in some pushback. “Patient satisfaction scores are a very real concern. When someone is sick and takes a day off work, they’re not leaving without a prescription – especially when the last provider wrote one for their same symptoms,” he said. “But this is a new day, and it’s up to the physician to educate their patients and stay strong.”

Hospitalists have access to accurate, inexpensive and quick diagnostic tests that can lead to targeted, effective treatment. This can arm the treating physician and patient with information that can put patients on a path to recovery without feeling like they are being dismissed.

Emerging guidance reflects important advances in research and development.

Most recently published in 2010, the Society for Healthcare Epidemiology of America (SHEA) and Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for C. diff are currently under review. This is critical because of the number of physicians still treating with metronidazole first, despite the fact that the largest randomized controlled clinical trial has shown that vancomycin is more effective.

“Since 2010, the landscape has changed dramatically,” said Stuart B. Johnson, MD, Professor, Department of Medicine, Loyola University, and Researcher at the Hines VA Hospital in Chicago.

“The past few years have ushered in a new age of understanding how and where C. diff colonizes, and the damaging toxins A and B that it produces.”

Considering that 25-30% of patients experience a CDI recurrence, it’s evident that metronidazole unnecessarily contributes to the failed treatment outcomes for patients. Metronidazole is less expensive, but has more side effects than oral vancomycin and is less effective in treating CDI.

Johnson provided an overview of the dramatic advances this space has seen in just the past few years.

Limitations of current guidelines include:
•       No mention of fidaxomicin, a narrow-spectrum antibiotic, which in 2011 was the first medication approved in 25 years for the treatment of C. diff associated diarrhea
•       Limited evidence for recommendations to treat severe, complicated CDI
•       Limited evidence for recommendations on recurrent CDI
•       Little mention of Fecal Microbiota Transplant (FMT)

########################

5.  Patient advocacy and awareness efforts can alter the course of CDI.
CDI survivors shared their experiences along their emotional journey – fear, disbelief, isolation, and depression. They also expressed gratitude at the validation, information and support they received from the patient advocacy community. Perhaps the greatest gift they have received is the empowerment to question their physicians about the necessity of antibiotics they have been prescribed in terms of risk of CDI.

“The hospital where I was treated initially seemed eager to have me leave. They offered no additional help. The C diff Foundation has been my greatest source of help. In turn, I feel I help myself cope best, when I help others to cope with the disease,” said Poole.

TO READ THIS ARTICLE IN ITS ENTIRETY AS PUBLISHED IN THE MD MAGAZINE 

PLEASE CLICK ON THE FOLLOWING LINK TO BE REDIRECTED —- THANK YOU

http://www.mdmag.com/medical-news/c-diff-foundation-highlights-latest-advances-in-the-battle-against-the-deadly-pathogen

 

Dale Gerding, MD, FACP, FIDSA, is Professor of Medicine at Loyola University Chicago, Research Physician at the Edward Hines Jr. VA Hospital. Additionally, Gerding is an infectious disease specialist and hospital epidemiologist, past president of the Society for Healthcare Epidemiology of America and past chair of the antibiotic resistance committee of SHEA. He is a fellow of the Infectious Diseases Society of America and past chair of the National and Global Public Health Committee and the Antibiotic Resistance Subcommittee of IDSA. His research interests include the epidemiology and prevention of Clostridium difficile, antimicrobial resistance, and antimicrobial distribution and kinetics.

The paper, “Burden of Clostridium difficile Infection in the United States,” was published in the New England Journal of Medicine.

The study, “Changing epidemiology of Clostridium difficile infection following the intriduction of a national ribotyping-based surveillance scheme in England,” was published in the journal Clinical Infectious Diseases.

The study, “Prevalence of antimicrobial use in US acute care hospitals,” was published in JAMA.

The paper, “Vancomycin, metronidazole, or toleyamer for Clostridium difficile infection: results from two multinaionalm randomized, controlled trials,” was published in Clinical Infectious Diseases.

The study, “A Randomized Placebo-controlled Trial of Saccharomyces boulardii in Combination with Standard Antibiotics for Clostridium difficile disease,” was published in JAMA.

C Diff Foundation Is Approved For Google Ad Grant To Promote Clostridium difficile (C.diff.) Prevention, Treatments, Environmental Safety, And Support Worldwide

 

The C Diff Foundation announces that it has been approved  for a Google Ad Grant equivalent to about USD 10,000 per month .  Google offers organizations free access to Google tools like Gmail, Google Calendar, Google Drive, Google Ad Grants,

“Nearly half a million Americans suffer from Clostridium difficile (C. diff.) infections in a single year. With annual fatalities close to 29,000 a year, it’s a global problem that affects every community,” explains Nancy Caralla, Executive Director and Foundress of the
C Diff Foundation. “With the support of companies like Google, we can further raise C. diff. awareness, provide information and support  and save lives worldwide.”

We’ are truly appreciative to have Google Ad Grants as part of the C Diff Foundation’s  C. diff. educational and advocacy  program and we are confident that the AdWords Grant will help the C Diff Foundation deliver additional support to patients, their families, and healthcare professionals worldwide.

With the Google Ad Grant the C Diff Foundation is able to help raise C. diff. awareness through education about research being conducted by the government, industry, and academia; and better advocacy on behalf of patients, healthcare professionals, and researchers worldwide working to address the public health threat posed by this devastating infection.

About the C Diff Foundation:
The C Diff Foundation is a leading nonprofit 501(c)(3) organization, established in 2012 and dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. The Foundation’s founder is a Nurse and after suffering through C. difficile infections herself and witnessing the loss of her father, whose life was claimed by C. difficile involvement, the
C Diff Foundation came to fruition.

The C Diff Foundation, with their Volunteer Patient Advocates, successfully “Raise C. diff. Awareness” nationwide and in 38 countries, and host a Nationwide information Hot-Line (1-844-FOR-CDIF) which also supports health care providers and patients to manage through the difficulties of a C. diff. infection.

 

Twitter:          @cdiffFoundation   #cdiff2016

Face Book:   https://www.facebook.com/CdiffFoundationRadio

A World of Thanks To the C Diff Foundation Volunteer Patient Advocates Around the Globe

National Volunteers Week     #NVW2016

 

Did you know that it is  NATIONAL VOLUNTEER WEEK
April 10-16, 2016

President Richard Nixon established National Volunteer Week with an executive order in 1974, as a way to recognize and celebrate the efforts of volunteers. Every sitting U.S. president since Nixon has issued a proclamation during National Volunteer Week (as have many U.S. mayors and governors).  Since then, the original emphasis on celebration has widened; the week has become a nationwide effort to urge people to get out and volunteer in their communities.

To each C Diff Foundation Volunteer Patient Advocate, , on behalf of all the staff and the thousands of members around the globe we want to say THANK YOU!

Your continued support and efforts contribute in a significant way to our mission of educating, and advocating for C. diff. infection prevention, treatments, and environmental safety awareness worldwide.

November marked our third  year in “Raising C. diff. infection Awareness” campaign and we thank the many organizations who supported and contributed by sharing information with others.  We are all working toward a shared goal in witnessing a reduction of newly diagnosed C. diff. cases and “None of us can do this alone…..all of us can do this TOGETHER!”

We celebrate our volunteers and this week stands as a reminder that our daily work sharing information, educating, and advocating for C. diff. infections, remains not only critical but it is urgent.

We do not know when new interventions to prevent, to treat, and protect our environments with products that will  eradicate C. diff. spores will become available to the public.  The good news is that we do know that there are many positive interventions presently in clinical trials, which give us all HOPE.

Visit the website for updates and feel free to inquire if you or a loved one would be considered a candidate to participate in an ongoing clinical trial:

 https://cdifffoundation.org/clinical-trials-2/

This is why acts of sharing the C Diff Foundation literature during every opportunity quickly opens doors of knowledge helping others learn how to prevent acquiring this painful and life-threatening infection, treatments available, and disinfecting products with EPA Registered C. diff. kill for environmental safety–  to  help save lives.

Reminder that there is always information and support  available and  only a phone call away 1-844-FOR-CDIF

The C Diff Foundation Volunteer Patient Advocates build awareness, help build support and provide education of C. difficile infection prevention, treatments, and environmental safety measures  to patients, survivors  their families and community healthcare professional centers/offices.  They also  guide individuals in giving a voice to patients, survivors and their families on healthcare-related infections, informing the public,  health-care providers (hospitals, healthcare professionals, etc.), organizations of health-care professionals, the educational world, with the medical, Governmental agencies, and pharmaceutical research communities.

We provide our Volunteer Patient Advocates with the necessary tools, and updates to generate positive results.

Do you have a few extra minutes to share vital information with others to raise C diff. infection awareness in your community?

By becoming a C Diff Foundation Volunteer Patient Advocate you will make a BIG difference and help spare others the pain, suffering, and tragedy of loosing a loved one that is caused by a C. diff. infection.

Contact our office for additional information and register today by e-mailing the C Diff Foundation your name and a valid mailing address to receive an official  C Diff Foundation Volunteer Patient Advocate Packet

info@cdifffoundation.org

On this day, and throughout the year ahead, we want you to be confident that your Volunteer Membership in the Foundation is bringing important information out into the communities and throughout the world through the educational brochures, cards, letters, and from sharing your own personal experiences with others.  Please be sure to share your journey with others in need of “HOPE” on the C. diff. Survivors Alliance Network website  http://www.cdiffsurvivors.org

Your continued donations received during the year are always appreciated. Your gifts assist the Foundation in promoting C. diff. infection prevention, treatments, and environmental safety education, and advocacy to healthcare professionals, families, patients, and communities world-wide.  We are grateful for your assistance, dedication, and support and we hope the Foundation has also been helpful to you.  If you have any suggestions about how we can serve others better or share the information more effectively, please let us know.  You are welcome to email, telephone, or write to the Foundation at any time.

We certainly look forward to your continued Volunteer Membership in the Foundation.  There is so much more that needs to be accomplished and we continue to move forward together promoting our mission, which is entirely dedicated for the good of others.

May you and your families experience continued HOPE for good health, happiness, and peace throughout the year.

Thank You for helping prevent further pain and suffering worldwide by sharing in the

C Diff Foundation’s mission today.